The Role of PARP Inhibitors in Ovarian Cancer

home / peer-exchange / the-role-of-parp-inhibitors--in-ovarian-cancer
Ovarian Cancer Overview

EP. 1: Ovarian Cancer Overview

November 27th 2019

Watch

Ovarian Cancer Diagnostic Process

EP. 2: Ovarian Cancer Diagnostic Process

November 27th 2019

Watch

Frontline Treatment and Neoadjuvant Chemotherapy

EP. 3: Frontline Treatment and Neoadjuvant Chemotherapy

November 27th 2019

Watch

The Rationale for Using PARP Inhibitors

EP. 4: The Rationale for Using PARP Inhibitors

November 27th 2019

Watch

The Supporting Role of Oncology Pharmacists

EP. 5: The Supporting Role of Oncology Pharmacists

November 27th 2019

Watch

Pharmacist’s Role: Raising Awareness for Clinicians

EP. 6: Pharmacist’s Role: Raising Awareness for Clinicians

November 27th 2019

Watch

The Importance of HRD Testing

EP. 7: The Importance of HRD Testing

November 27th 2019

Watch

PRIMA Trial Overview

EP. 8: PRIMA Trial Overview

November 27th 2019

Watch

PAOLA-1 Trial Overview

EP. 9: PAOLA-1 Trial Overview

November 27th 2019

Watch

New PARP Inhibitor: The VELIA Regimen

EP. 10: New PARP Inhibitor: The VELIA Regimen

November 27th 2019

Watch

The Specialty Pharmacy Program

EP. 11: The Specialty Pharmacy Program

November 27th 2019

Watch

Platinum-Sensitive vs Platinum-Resistant Recurrence

EP. 12: Platinum-Sensitive vs Platinum-Resistant Recurrence

November 27th 2019

Watch

Second-Line Options After First-Line Bevacizumab

EP. 13: Second-Line Options After First-Line Bevacizumab

November 27th 2019

Watch

Platinum Sensitive Disease: When to Use PARPi

EP. 14: Platinum Sensitive Disease: When to Use PARPi

November 27th 2019

Watch

Chemo-Free Regimen in Later-Line Settings

EP. 15: Chemo-Free Regimen in Later-Line Settings

November 27th 2019

Watch

Treating Recurrent Patients

EP. 16: Treating Recurrent Patients

November 27th 2019

Watch

© 2023 MJH Life Sciences

All rights reserved.